BCRX - Latest News
BioCryst Pharmaceuticals, Inc. (BCRX), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $2.12B. Beta to the broader market is 0.56.
The article list below shows the most recent BCRX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent BCRX Headlines
Biopharma Stock With Layers of Technical Support in Place
schaeffersresearch.com - Sep 21, 2026
After its most recent pullback, biopharmaceutical stock BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) bounced off the $8 level and has now reclaimed the
BioCryst Eyes $1B Rare-Disease Future Through External Innovation
marketbeat.com - Sep 18, 2026
BioCryst Pharmaceuticals NASDAQ: BCRX is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioed
4 Biotech Stocks to Watch as Potential Takeover Targets
zacks.com - Sep 18, 2026
Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com - Sep 15, 2026
BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity
seekingalpha.com - Sep 11, 2026
BioCryst Pharmaceuticals, Inc. 's shares remain under pressure.
How News Affects BCRX Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track BCRX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked BCRX news questions
- What is the latest BCRX news headline?
- The most recent BCRX headline (Sep 21, 2026) is "Biopharma Stock With Layers of Technical Support in Place". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the BCRX news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What BCRX news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual BCRX options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.